Understanding mechanisms and documenting plausibility of palliative interventions for dyspnea

Current Opinion in Supportive and Palliative Care

Volumn 5, Issue 2, 2011, Pages 71-76

  Mahler, Donald A ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Afferent impulses; Central nervous system; Endogenous opioids; Neuromodulation; Sensory receptors

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ENDORPHIN; NALOXONE; NARCOTIC ANTAGONIST;

CENTRAL NERVOUS SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; DYSPNEA; EFFERENT NERVE; HUMAN; PALLIATIVE THERAPY; PANIC; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; SENSORY NERVE; SENSORY RECEPTOR;

AFFERENT PATHWAYS; CENTRAL NERVOUS SYSTEM; DYSPNEA; EFFERENT PATHWAYS; ENDORPHINS; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; NEUROTRANSMITTER AGENTS; PALLIATIVE CARE; PANIC DISORDER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SENSORY RECEPTOR CELLS;

EID: 80052309357     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e328345bc84     Document Type: Review

References (38)

1. von Leupoldt A, Balewski S, Petersen S, et al. Verbal descriptors of dyspnea in patients with COPD at different intensity levels of dyspnea. Chest 2007; 132:141-147. (Pubitemid 47068214)
2. Official Statement of the American Thoracic Society. Dyspnea: mechanisms, assessment, and management. A consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999; 159:321-340.
3. Carrieri-Kohlman V, Donesky-Cuenco D, Park SK, et al. Additional evidence for the affective dimension of dyspnea in patients with COPD. Res Nurs Health 2010; 33:4-19.
4. Banzett RB, Pedersen SH, Schwartzstein RM, Lansing RW. The affective dimension of laboratory dyspnea: air hunger is more unpleasant than work/ effort. Am J Respir Crit Care Med 2008; 177:1384-1390. (Pubitemid 351860917)
5. Davenport PW, Vovk A. Cortical and subcortical central neural pathways in respiratory sensations. Respir Physiol Neurobiol 2009; 167:72-86.
6. von Leupoldt A, Dahme B. Cortical substrates for the perception of dyspnea. Chest 2005; 128:345-354. (Pubitemid 40994494)
7. Burki NK, Lee LY. Mechanisms of dyspnea. Chest 2010; 138:1196-1201.
8. O'Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 2007; 4:145-168. (Pubitemid 46743309)
9. Taguchi O, Kikuchi Y, Hida W, et al. Prostaglandin E2 inhalation increases the sensation of dyspnea during exercise. Am Rev Respir Dis 1992; 145:1346-1349.
10. Peiffer C, Costes N, Herve P, Garcia-Larrea L. Relief of dyspnea involves a characteristic brain activation and a specific quality of sensation. Am J Respir Crit Care Med 2008; 177:440-449. (Pubitemid 351317588)
11. von Leupoldt A, Sommer T, Kegat S, et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med 2008; 177:1026-1032. (Pubitemid 351717598)
12. 2 in mechanically ventilated quadriplegics. Respir Physiol 1989; 76:53-67.
13. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis 1993; 148:1351-1357. (Pubitemid 23326038)
14. Smoller JW, Pollack MH, Otto MW, et al. Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am J Respir Crit Care Med 1996; 154:6-17.
15. Livermore N, Butler JE, Sharpe L, et al. Panic attacks and perception of inspiratory resistive loads in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178:7-12. (Pubitemid 351919187)
16. Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev 2009; 89:1379-1412.
17. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995; 332:1685-1690.
18. Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci 2000; 66:2221-2231. (Pubitemid 30256621)
19. Clement-Jones V, Besser GM. Clinical perspectives in opioid peptides. Br Med Bull 1983; 39:95-100. (Pubitemid 13220734)
20. Santiago TV, Edelman NH. Opioids and breathing. J Appl Physiol 1985; 59:1675-1685.
21. Bellofiore S, Di Maria GU, Privitera S, et al. Endogenous opioids modulate the increase in ventilatory output and dyspnea during severe acute bronchoconstriction. Am Rev Respir Dis 1990; 142:812-816. (Pubitemid 20344649)
22. Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J 2009; 33:771-777.
23. Varkey B. Opioids for palliation of refractory dyspnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2010; 16:150-154.
24. Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010; 137:674-691.
25. Sudo T, Hayashi F, Nishino T. Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats. Am J Respir Crit Care Med 2000; 162:971-975.
26. Minowa Y, Ide T, Nishino T. Effects of inhaled furosemide on CO(2) ventilatory responsiveness in humans. Pulm Pharmacol Ther 2002; 15:363-368.
27. Moosavi SH, Binks AP, Lansing RW, et al. Effect of inhaled furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol 2007; 156:1-8. (Pubitemid 46228091)
28. Nishino T, Ide T, Sudo T, Sato J. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med 2000; 161:1963-1967. (Pubitemid 30418137)
29. Ong KC, Kor AC, Chong WF, et al. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169:1028-1033.
30. Jensen D, Amjadi K, Harris-McAllister V, et al. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax 2008; 63:606-613. (Pubitemid 351969253)
31. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126:926-934. (Pubitemid 39258050)
32. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084-1091. (Pubitemid 35178706)
33. Calverley P, Pauwels R, Vestbo J, et al. Trial of inhaled steroids and longacting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456.
34. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009; 151:517-527.
35. Sibuya M, Yamada M, Kanamaru A, et al. Effect of chest wall vibration on dyspnea in patients with chronic respiratory disease. Am J Respir Crit Care Med 1994; 149:1235-1240. (Pubitemid 24147065)
36. Ahsin S, Saleem S, Bhatti AM, et al. Clinical and endocrinological changes after electro-acupuncture treatment in patients with osteoarthritis of the knee. Pain 2009; 147:60-66.
37. Lee HJ, Lee JH, Lee EO, et al. Substance P and beta-endorphin mediate electro-acupuncture induced analgesia in mouse cancer pain model. Acupunct Electrother Res 2009; 34:27-40.
38. Jarmukli NF, Ahn J, Iranmanesh A, Russell DC. Effect of raised plasma beta endorphin concentrations on peripheral pain and angina thresholds in patients with stable angina. Heart 1999; 82:204-209. (Pubitemid 29362872)